Dr. Raheleh Roudi

Researcher
University of Medical Sciences Tehran, Iran

Highest Degree
Ph.D. in Molecular Medicine from Iran University of Medical Sciences, Tehran, Iran

My URL
https://livedna.org/98.29788

Share this Profile

Area of Interest:

Molecular Sciences
Medicine
Protein Isolation
Gene Expression
Stem Cell

Selected Publications

  1. Tartarone, A., G. Roviello, R. Lerose, R. Roudi, M. Aieta and P. Zoppoli, 2019. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: A meta-analysis. Future Oncol. J., 10.2217/fon-2018-0868.
    CrossRef  |  Direct Link  |  

  2. Sun, X., R. Roudi, T. Dai, S. Chen and B. Fan et al., 2019. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer, 10.1186/s12885-019-5701-6.
    CrossRef  |  Direct Link  |  

  3. Roviello, G., D.A. Angelo, R. Roudi, R. Petrioli and E. Mini, 2019. Novel agents in heavily pretreated metastatic gastric cancer: More shadows than lights. J. Oncol., 10.1155/2019/5692317.
    CrossRef  |  Direct Link  |  

  4. Mohsenzadegan, M., R.W. Peng and R. Roudi, 2019. Dendritic cell/cytokine‐induced killer cell‐based immunotherapy in lung cancer: What we know and future landscape. J. Cell Physiol., 5: 122-128.
    CrossRef  |  Direct Link  |  

  5. Kalantari, E., M. Abolhasani, R. Roudi, M.M. Farajollahi and Z. Madjd et al., 2019. Co‐expression of TLR‐9 and MMP‐13 is associated with the degree of tumour differentiation in prostate cancer. Int. J. Exp. Pathol., 10.1111/iep.12314.
    CrossRef  |  Direct Link  |  

  6. Sedaghat, S., E. Gheytanchi, M. Asgari, R. Roudi, H. Keymoosi and Z. Madjd, 2017. Expression of cancer stem cell markers OCT4 and CD133 in transitional cell carcinomas. Appl. Immunohistochem. Mol Morphol., 25: 196-202.
    CrossRef  |  Direct Link  |  

  7. Korourian, A., R. Roudi, A. Shariftabrizi, E. Kalantari, K. Sotoodeh and Z. Madjd, 2017. Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness. Clin. Exp. Med., 17: 505-517.
    CrossRef  |  Direct Link  |  

  8. Roudi, R., Z. Madjd, M. Ebrahimi, A. Najafi, A. Korourian, A. Shariftabrizi and A. Samadikuchaksaraei, 2016. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. Tumour Biol., 37: 11843-11859.
    CrossRef  |  Direct Link  |  

  9. Roudi, R., G. Haji, Z. Madjd, A. Shariftabrizi and M. Mehrazma, 2016. Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer: A tissue microarray analysis. J. Cancer Res. Ther., 12: 1065-1069.
    Direct Link  |  

  10. Roudi, R., E. Kalantari, A. Keshtkar and Z. Madjd, 2016. Accuracy of c-KIT in Lung Cancer prognosis; A systematic review protocol" instead of c-KIT expression in Lung Cancer prognostic evaluation- A systematic review protocol. Asian Pac. J. Cancer Prev., 17: 863-866.
    Direct Link  |  

  11. Rasti, A., M. Mehrazma, Z. Madjd, A.A. Keshtkar, R. Roudi and S. Babashah, 2016. Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: A systematic review protocol. BMJ Open, 10.1136/bmjopen-2015-009667.
    CrossRef  |  Direct Link  |  

  12. Kalantari, E., F.H. Saadi, M. Asgari, A. Shariftabrizi, R. Roudi and Z. Madjd, 2016. Increased expression of ALDH1A1 in prostate cancer is correlated with tumor aggressiveness: A tissue microarray study of iranian patients. Applied Immunohistochem. Mol. Morphol., 25: 592-598.
    CrossRef  |  PubMed  |  Direct Link  |  

  13. Erfani, E., R. Roudi, A. Rakhshan, M.N. Sabet, A. Shariftabrizi and Z. Madjd, 2016. Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes. Int. J. Biol. Markers, 31: 53-61.
    CrossRef  |  Direct Link  |  

  14. Roudi, R., A. Korourian, A. Shariftabrizi and Z. Madjd, 2015. Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes. Cancer Invest, 33: 294-302.
    CrossRef  |  Direct Link  |  

  15. Roudi, R., Z. Madjd, M. Ebrahimi, F.S. Samani and A. Samadikuchaksaraei, 2014. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Cell Mol. Biol. Lett., 19: 23-36.
    CrossRef  |  Direct Link  |  

  16. Roudi, R., Z. Madjd, A. Korourian, M. Mehrazma, S. Molanae, M.N. Sabet and A. Shariftabrizi, 2014. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. Cancer Biomark, 14: 457-467.
    CrossRef  |  Direct Link  |  
Member since July, 2019